The process of drug development is one of the most demanding undertakings in modern science. Bringing a new medicine from laboratory hypothesis to patient prescription takes an average of 10 to 15 years and billions of dollars in investment. At every stage, it also generates a massive documentation burden that few organizations can manage efficiently.
In addition to that, not every regulatory framework divides the drug development process the same way. For instance, the FDA's patient-facing guidance breaks it into five steps, separating drug discovery from preclinical research.
However, across the pharmaceutical industry, these two pre-human phases are widely consolidated into a single stage, as both share the same regulatory milestone: the Investigational New Drug (IND) application.
The 4 stages of drug development span from initial bench research through perpetual post-market surveillance:
Drug Discovery and Preclinical Research
Clinical Trials (Phases I-IV)
Regulatory Review and Submission
Post-Market Surveillance and Pharmacovigilance
The documentation workload intensifies at every transition point, and medical writing teams absorb the operational cost of each delay. AI-powered authoring is increasingly deployed across the entire life cycle, not as a peripheral efficiency tool but as a core capability for managing that documentation at scale.
Stage 1: Drug Discovery and Preclinical Research
Drug discovery begins with target identification: locating genes, proteins, or other molecular entities believed to play a role in a specific disease. Once a viable target is established, compound screening follows, evaluating hundreds or thousands of candidate molecules for their potential to interact with the target.
Testing then progresses through two sequential stages before the IND application can be filed:
In vitro testing: Candidate compounds are evaluated in cell cultures and controlled laboratory settings to assess biological activity, toxicity profiles, and mechanisms of action, enabling rapid, relatively low-cost screening before committing to animal studies.
In vivo testing: Promising candidates are tested in animal models to evaluate pharmacokinetics (how the drug is absorbed, distributed, metabolized, and excreted) and pharmacodynamics (what the drug does in the body), as well as safety at escalating doses.
The IND is the regulatory milestone that closes this stage. It’s a complete submission to the FDA requesting authorization to begin human testing. It requires:
Nonclinical study reports
Proposed clinical protocols
Investigator qualifications
Manufacturing information
All components must meet regulatory submission standards.
The Documentation Challenge: Preclinical data is generated across multiple laboratories, CROs, and data formats, making it difficult to synthesize into the nonclinical summaries required for IND submission.
How AuroraPrime Helps: The platform addresses this through automated nonclinical study report drafting and CTD Module 2.6 Nonclinical Summary generation, CTD Module 4-aligned templates, and structured data ingestion from multiple preclinical sources, compressing the time from data readout to IND-ready documentation.
Stage 2: Clinical Trials
Following IND authorization, a candidate drug enters clinical development: the systematic, regulatory-supervised evaluation of safety and efficacy in human subjects. Clinical trials represent the longest phase of the drug development timeline and process, often spanning 6 to 7 years of pre-approval testing.
The documentation workload across those phases is substantial and accumulates continuously, often across multiple concurrent trials. Key document types generated throughout clinical development include:
Clinical protocols and protocol amendments
Safety narratives and individual case safety reports
Interim and final Clinical Study Reports (CSRs)
Periodic safety submissions, including DSURs and PSURs
Regulatory correspondence
As an AI writing solution for life sciences, AuroraPrime supports that documentation volume across all four phases from a single authoring environment.
Phase I: Safety and Dosage Tolerability
A small cohort of about 20 to 80 participants, typically healthy volunteers, receives escalating doses to establish the drug's safety profile, maximum tolerated dose, and pharmacokinetic parameters in humans. The primary objective is to confirm that the compound is safe enough to proceed to broader testing.
Key documents generated:
Investigator's Brochure
Informed consent forms
Phase I clinical protocol
Initial adverse event safety narratives
How AuroraPrime Helps: AuroraPrime supports Phase I authoring through AI-copiloted Investigator's Brochure drafting, automated reuse of content from preclinical data, and protocol template configuration aligned with FDA and ICH standards.
Phase II: Efficacy and Dose Optimization
Phase II expands to a cohort of 100 to 300 patients with the target condition to assess preliminary efficacy, refine the optimal therapeutic drug dose, and evaluate side effects in the intended treatment population. The data must demonstrate proof of concept before sponsors commit to the cost and scale of pivotal trials.
Study designs evolve frequently during Phase II, generating protocol amendments throughout the development life cycle. Key documentation at this phase includes:
Interim Clinical Study Reports (CSRs)
Individual case safety reports
Development Safety Update Report (DSUR) submissions
How AuroraPrime Helps: The platform automates protocol amendment drafting triggered by upstream protocol changes and generates patient safety narratives, reducing manual authoring time by up to 95%.
Phase III: Pivotal Large-Scale Trials
Phase III is the turning point in the drug development process. Between 1000 and 3,000 or more patients across multiple sites and geographies receive the drug, enabling statistically powered confirmation of efficacy and a full safety profile at therapeutic scale. Successful completion generates the definitive clinical evidence required for a marketing authorization application.
Documentation reaches its peak at this phase. Concurrent authoring tasks include:
Full CSRs for each completed study, authored simultaneously across trial sites
Continuous TFL (tables, figures, and listings) data updates
Integrated clinical summaries for CTD Modules 2.5 and 2.7, prepared in parallel with ongoing trials
Annual DSUR filings, due within 60 calendar days of the data lock point under ICH E 2 F
How AuroraPrime Helps: The platform directly addresses that peak burden through AI-driven CSR first-draft generation with up to 90% reduction in draft time, one-click TFL data synchronization, batch content generation across multiple concurrent study reports, and automated DSUR authoring with multi-source data integration.
Phase IV: Post-Market Clinical Trials
Phase IV studies are conducted after regulatory approval in real-world patient populations far broader than those in pre-approval trials, including elderly patients, those with comorbidities, and populations historically excluded from earlier phases of clinical trials. The primary objective is long-term safety surveillance: detecting rare adverse events that were statistically invisible at trial scale and generating real-world evidence for ongoing regulatory compliance.
Key documents generated at this phase include:
Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs)
Periodic Adverse Drug Experience Reports (PADERs) for FDA submissions under 21 CFR 314.80
Real-world evidence summaries
Product label amendments
How AuroraPrime Helps: The platform automates PSUR and PBRER drafting aligned with ICH E 2 C(R 2), provides PADER-compliant templates, and deploys dynamic literature intelligence to flag emerging safety signals for integration into aggregate report narratives.
